Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Omnicare : Omnicare : Omnicare Specialty Care Group Expands Pharmacy and Brand Support Services for DIFICID® (fidaxomicin)



Omnicare : Omnicare : Omnicare Specialty Care Group Expands Pharmacy and Brand
             Support Services for DIFICID® (fidaxomicin) tablets

ORLANDO, February 4, 2013 - Omnicare Specialty Care Group (SCG) has expanded
its service offering for Optimer's DIFICID^® (fidaxomicin) tablets to include
brand support in addition to specialty pharmacy dispensing services. DIFICID
is a macrolide antibacterial drug indicated in adults 18 years of age and
older for the treatment of Clostridium difficile-associated diarrhea.

Omnicare SCG's specialty pharmacy, Advanced Care Scripts (ACS) supports
Optimer's DIFICID Rx Assist(TM) program, which facilitates a continuum of care
for patients as they transition from the hospital to the home or other
setting.  

In managing DIFICID Rx Assist, ACS supports an access and reimbursement
hotline and the application process for the Optimer Patient Assistance
Program. The new model also includes support for the DIFICID Co-Pay Assistance
Program, which provides up to $200 toward a commercially insured patient's
copayment obligation for 1 DIFICID prescription up to 20 tablets per calendar
year.  "We are excited to be working with Optimer in this expanded capacity,"
said David Hileman, Senior Vice President of Omnicare Specialty Care
Group. "The DIFICID Rx Assist Program will help address potential issues and
challenges encountered in today's marketplace, including education and access
to therapy. Each aspect of the program is designed to help facilitate the
continuum of care for patients."

ACS manages and dispenses specialty medications in multiple disease
categories, including cancer, infectious diseases, auto-immune disorders,
multiple sclerosis and hemophilia. Its expertise across both the specialty and
long-term care channels allows it to provide comprehensive solutions for
prescribers and patients.

About Omnicare Specialty Care Group
Omnicare Specialty Care Group (SCG) is a division of Omnicare, Inc., a Fortune
400 company and provider of comprehensive pharmaceutical services based in
Cincinnati, Ohio. Omnicare SCG is a combination of synergistic tenured
companies with a focused approach to pharmaceutical brand solutions. Together,
Omnicare SCG brings specialists in reimbursement methods, clinicians practiced
in medication therapy management for chronic disease states, and distribution
channel expertise. Solutions are tailored to drive product access by solving
challenges faced by patients and their caregivers, physicians, payers and
manufacturers. Custom programs are led by a single management team across the
organizational platforms, allowing coordination of resources and assets to
support positive outcomes for our patients. For more information, visit
www.omnicarescg.com

About Omnicare
Omnicare, Inc., a Fortune 400 company based in Cincinnati, Ohio, provides
comprehensive pharmaceutical services to patients and providers across North
America.  As the market-leader in professional pharmacy, related consulting
and data management services for skilled nursing, assisted living and other
chronic care institutions, Omnicare leverages its unparalleled clinical
insight into the geriatric market along with some of the industry's most
innovative technological capabilities to the benefit of its long-term care
customers.  Omnicare also provides key commercialization services for the
bio-pharmaceutical industry and end-of-life disease management through its
Specialty Care Group.  For more information, visit http://www.omnicare.com/.

Important Safety Information

DIFICID is contraindicated in patients with hypersensitivity to fidaxomicin or
to any of the excipients in the formulation. DIFICID should not be used for
systemic infections. Only use DIFICID for infection proven or strongly
suspected to be caused by C. difficile. Prescribing DIFICID in the absence of
a proven or strongly suspected C. difficile infection is unlikely to provide
benefit to the patient and increases the risk of the development of
drug-resistant bacteria. The most common adverse reactions are nausea (11%),
vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia
(2%) and neutropenia (2%)

                                    # # #

Contact:

Media:
Ed Loyd
(513) 719-0808
ed.loyd@omnicare.com

Business:
David Hileman
(502) 213-1104
david.hileman@omnicare.com

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Omnicare via Thomson Reuters ONE
HUG#1675140
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement